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Abstract
Background: This study aimed to evaluate the current status of secondary debulking surgery (SDS) and tertiary
debulking surgery (TDS; performed for recurrence after SDS) and to assess the overall survival after recurrence of
Müllerian epithelial cancer in Japan. We also evaluated the data of patients who underwent a fourth debulking
surgery (i.e., quaternary debulking surgery (QDS)).
Methods: We conducted a retrospective study of 164 patients with recurrent Müllerian epithelial cancers (i.e.,
ovarian, tubal, and peritoneal cancers). The SDS was performed between January 2000 and September 2014 in 20
Japanese hospitals. Clinicopathological data were collected and analyzed.
Results: Of the 164 patients, 66 patients did not have a recurrence or died after SDS. Ninety-eight patients had a
recurrence after SDS. Forty-three of the 98 patients underwent TDS; 55 of the 98 patients did not undergo TDS and
were classified into the non-TDS group. The overall survival (OS) after SDS was significantly better in the TDS group
than in the non-TDS group. The median OS after SDS was 123 and 42 months in the TDS group and non-TDS
group, respectively. Of the 43 patients who received TDS, 11 patients were further treated with QDS. The median
OS after SDS was 123 months for patients who underwent QDS.
Conclusions: This multicenter study on the prognosis of post-SDS is apparently the first report on QDS in Japan.
Patients undergoing TDS have a good prognosis, compared to patients in the non-TDS group. Novel drugs are
being evaluated; however, debulking surgery remains a necessary treatment for recurrence.
Keywords: Müllerian epithelial cancer, Recurrence, Secondary debulking surgery, Tertiary debulking surgery,
Quaternary debulking surgery
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Background
The treatment of recurrent ovarian cancer consists
mainly of chemotherapy. However, secondary debulking
surgery (SDS; also known as secondary cytoreductive
surgery) is an effective option if the patients are selected
carefully [1–4]. There are very few reports on Japanese
patients treated with SDS, although there is one previous
report on 44 Japanese patients [5]. Secondary debulking
surgery seems to be effective if complete resection has
been achieved. The AGO DESKTOP OVAR Trial
(DESKTOP I trial) showed that only complete surgery
was associated with prolonged survival in patients with
recurrent ovarian cancer [6]. Moreover, the trial pre-
sented a predictive score for the resectability of recur-
rent ovarian cancer. This score model was based on the
performance status, the presence of ascites, and the out-
come of the primary surgery [6, 7]. The DESKTOP II
trial was subsequently the first prospective multicenter
trial that successfully validated a clinical score that could
be used to predict complete resection [8].
Surgery after SDS (i.e., tertiary debulking surgery
(TDS)) is performed in highly selected cases and is rarely
reported [9–13]. Moreover, reports of a fourth debulking
surgery (i.e., quaternary debulking surgery (QDS)) are
even rarer [14–17]. If the efficacy of SDS can be proven,
the effectiveness of TDS or additional debulking surger-
ies should be studied.
With this in mind, the aims of this study were to
retrospectively analyze the data of patients with recur-
rent Müllerian epithelial cancers (i.e., ovarian, tubal, and
peritoneal cancers) and to assess the prognostic factors
and the current status of recurrence after SDS in Japan.
Methods
We designed a multicenter retrospective study, which
included 164 patients with recurrent Müllerian epithelial
cancer who were enrolled from 20 hospitals in Japan.
The Institutional Review Boards of each hospital ap-
proved this study. The patient selection criteria were as
follows: a complete response was achieved by the pri-
mary treatment, patients were histologically diagnosed
with Müllerian epithelial cancers (i.e., ovarian, tubal, and
peritoneal cancers), and SDS was performed between
January 2000 and September 2014. The performance sta-
tus of the patients was estimated to be 0 or 1, based on
the Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) criteria. The exclusion criteria were
as follows: a history of other cancer, patients who did
not achieve complete response by SDS or subsequent
chemotherapy, and patients who underwent palliative
surgery at first recurrence (therefore, it was not regarded
as SDS). The collected data about the initial treatment
included age at the initial diagnosis, clinical and patho-
logical stage (i.e., International Federation of Gynecology
and Obstetrics (FIGO) stage), histology, serum cancer
antigen-125 (CA125) level, and presence of residual
tumor (0, <10, or ≥10 mm) at the primary debulking
surgery (PDS). The data collected at recurrence included
age, platinum-free interval, serum CA125 level, presence
of peritonitis carcinomatosa, and presence of residual tu-
mors at SDS (0, <10, or ≥10 mm). The collected data at
the TDS (i.e., recurrence after SDS) were age, serum
CA125 level, presence of peritonitis carcinomatosa, site
of recurrence, and number of recurrence. Survival time
after SDS and data regarding TDS and QDS were also
collected. The absence of residual tumor (0 mm) was de-
fined as a complete surgery. The TDS group consisted of
patients who underwent debulking surgery for recur-
rence after SDS. Patients undergoing a fourth or fifth
debulking surgery were also included in the TDS group.
The non-TDS group consisted of patients who did not
undergo a TDS; these patients had not undergone sur-
gery for recurrence after the SDS.
The primary objective was to compare the overall sur-
vival (OS) in the TDS group with that in the non-TDS
group. The OS was the interval between the date of the
SDS and death. Most studies define OS as the survival
time from the initial diagnosis. However, in this study,
all patients underwent a SDS. The time between the pri-
mary treatment and recurrence ranged widely among
them; therefore, the definition of OS as the survival time
between the date of SDS and death was appropriate.
The secondary objective was to identify the character-
istics of the TDS group and the non-TDS group. The
platinum-free interval was the interval between the date
of the last infusion of platinum for the primary treat-
ment and the date of recurrence. Platinum resistance
was defined as recurrence within 6 months after the last
platinum treatment. Platinum partial sensitivity was de-
fined as recurrence between 6 and 12 months after plat-
inum treatment. Platinum sensitivity was defined as
recurrence after 12 months.
The differences in the background characteristics of
the patients were analyzed using the chi-square test. The
survival data were analyzed using the Kaplan–Meier
method and log-rank test. For all analyses, Statistical
Package for Social Science software (IBM SPSS Statistics
24; IBM, Armonk, NY) was used, and P < 0.05 was con-
sidered statistically significant.
Results
Figure 1 shows the inclusion criteria for data collection in
this study. One hundred sixty-four patients underwent
SDS in 20 hospitals. Sixty-six patients did not have a re-
currence or died after SDS. Ninety-eight patients had a re-
currence after SDS. Forty-three of the 98 patients were
classified into the TDS group. Tertiary debulking surgery
was performed in 15 hospitals. Among the TDS group, 11
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(25.6%) patients underwent QDS, 15 (34.9%) patients did
not undergo QDS, and 17 (39.5%) patients did not have a
recurrence or died after TDS.
Fifty-five of the 98 patients did not undergo TDS when
they had a recurrence after SDS, and they were classified
into the non-TDS group. The non-TDS patients were
treated with chemotherapy or the best supportive care.
Table 1 shows the main characteristics of the patients in
two groups at the time of initial diagnosis, SDS, and recur-
rence after SDS. The median ages of the patients at initial
diagnosis were 56.9 years (range, 35–74 years) and 54.2
(range, 27–77 years) in the TDS and non-TDS groups, re-
spectively. Forty-two (97.7%) patients in the TDS group
and 51 (92.7%) patients in the non-TDS group were diag-
nosed with ovarian cancer. No cases of tubal cancer were
included in the TDS group. There were only two (3.6%)
cases of tubal cancer in the non-TDS group. One (2.3%)
patient in the TDS group and two (3.6%) patients in the
non-TDS group had peritoneal cancer. Serous cystadeno-
carcinoma was the most common histological type (22
[51.2%] cases in the TDS group and 36 [65.5%] cases in
the non-TDS group). Complete surgery at PDS was per-
formed in 34 (79.1%) patients in the TDS group and 33
(60.0%) patients in the non-TDS group. Complete surgery
at SDS was performed in 38 (88.4%) patients in the TDS
group and 44 (80.0%) patients in the non-TDS group.
The median ages at TDS recurrence (i.e., recurrence
after SDS) were 61.5 years (range, 40–78 years) and
58.6 years (range, 33–80 years) in the TDS and non-TDS
groups, respectively. The CA125 levels at TDS recurrence
(i.e., recurrence after SDS) significantly differed between
the two groups (P = 0.040). Peritonitis carcinomatosa was
significantly different in the non-TDS patients (P = 0.042).
With regard to the sites of recurrence, more patients
showed recurrence in the peritoneal cavity in the non-
TDS group than in the TDS group (P = 0.009). In the TDS
and non-TDS groups, peritoneal recurrence occurred in
28 (65.1%) patients and 48 (87.3%) patients, respectively,
while extra-peritoneal recurrence occurred in 15 (34.9%)
patients and seven (12.7%) patients, respectively. Among
cases of extra-peritoneal recurrence in the TDS group, five
(33.3%) cases occurred in the lung; five (33.3%) cases oc-
curred in the brain; four (26.7%) cases occurred in the in-
guinal lymph nodes; and one (6.7%) case occurred in the
axilla. In the non-TDS group, the extra-peritoneal recur-
rence site was the lung in three (42.9%) cases, the medias-
tinal space in three (42.9%) cases, and the bone in one
(14.3%) case. With regard to the number of recurrence
sites, more patients presented with single-site recurrence
in the TDS group than in the non-TDS group (P = 0.013).
Solitary recurrence occurred in 24 (55.8%) TDS patients
and 17 (30.9%) non-TDS patients, and multiple recur-
rences occurred in 19 (44.2%) TDS patients and 38
(69.1%) non-TDS patients.
Among the 164 patients included in this study, 43 pa-
tients underwent TDS. The OS after SDS was significantly
better in the TDS group, compared to the non-TDS group
(P = 0.001; Fig. 2). The median OS after SDS was
123 months and 42 months in the TDS group and non-
TDS group, respectively.
Our study included 11 patients who underwent QDS
(Table 2). Moreover, two of the 11 QDS patients under-
went a fifth debulking surgery. Eight of the 11 patients
were alive at the conclusion of the study. The median
age of the 11 patients at QDS was 57 years (range, 52–
65 years), and the median OS after SDS was 123 months
(range, 43–138 months; Table 2).
Discussion
This study aimed to clarify the current status of SDS
and TDS in Japan because few patients have undergone
SDS or TDS in Japan and the current status of SDS and
Fig. 1 The inclusion criteria of patients in this study
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TDS is unknown. We found no significant difference in
the characteristics between the TDS and non-TDS
groups at the primary treatment and at the first recur-
rence, except for residual disease at PDS. However, a
significant difference was noted between the TDS and
non-TDS groups in the survival time from the SDS (P <
0.001, Fig. 2). It has been previously demonstrated that
SDS shows an advantage in terms of longer OS for
highly selected patients [18, 19]; however, the predictors
of survival in these patients remain unclear.
It has been reported that ascites (<500 ml) is a prognos-
tic factor and predictor of complete surgery [6, 7]. In this
study, it was difficult to collect data concerning ascites be-
cause amount of ascites was not measured in most pa-
tients. Therefore, we evaluated ascites by using the
presence of peritonitis carcinomatosa. In the present
study, only three (7.0%) patients and four (7.3%) patients
relapsed with carcinomatous peritonitis in the TDS and
non-TDS groups at SDS, respectively. It is possible that
the patients with ascites were treated largely by chemo-
therapy instead of SDS, although this study has no data on
the non-SDS patients (i.e., patients who did not receive
Table 1 Clinical characteristics of the tertiary debulking surgery
(TDS) group and non-TDS group
Characteristics TDS (n = 43) Non-TDS (n = 55) P value
Primary
Age, median (range), years 56.9 (35–74) 54.2 (27–77)
<60 24 (55.8%) 35 (63.6%) 0.432
≧60 19 (44.2%) 20 (36.4%)
Cancer
Ovary 42 (97.7%) 51 (92.7%) 0.415
Fallopian tube 0 (0%) 2 (3.6%)
Peritoneum 1 (2.3%) 2 (3.6%)
FIGO stage
I, II 10 (23.3%) 13 (23.6%) 0.965
III, IV 33 (76.7%) 42 (76.4%)
Histology
Serous 22 (51.2%) 36 (65.5%) 0.333
Endometrioid 6 (14.0%) 4 (7.3%)
Clear cell 10 (23.3%) 6 (10.9%)
Mucinous 2 (4.7%) 3 (5.5%)
Others 3 (7.0%) 6 (10.9%)
CA 125 (U/ml)
< 100 10 (23.3%) 7 (12.7%) 0.086
≧100 21 (48.8%) 38 (69.1%)
Missing 12 (27.9%) 10 (18.2%)
Residual disease at PDS, mm
0 34 (79.1%) 33 (60.0%) 0.035
0-10 8 (18.6%) 11 (20%)
≧10 1 (2.3%) 10 (18.2%)
Missing 0 (0%) 1 (1.8%)
Recurrence at SDS
Age, median (range), years 59.5 (40–76) 56.8 (32–79)
<60 20 (46.5%) 30 (54.5%) 0.430
≧60 23 (53.5%) 25 (45.5%)
Platinum-free interval
<6 months 4 (9.3%) 3 (5.5%) 0.09
6–12 months 13 (30.2%) 9 (16.4%)
≧12 months 22 (51.2%) 42 (76.4%)
Missing 4 (9.3%) 1 (1.8%)
CA 125 (U/ml)
<100 32 (74.4%) 37 (67.3%) 0.410
≧100 8 (18.6%) 14 (25.5%)
Missing 3 (7.0%) 4 (7.3%)
Peritonitis carcinomatosa
No 39 (90.7%) 48 (87.3%) 0.920
Yes 3 (7.0%) 4 (7.3%)
Table 1 Clinical characteristics of the tertiary debulking surgery
(TDS) group and non-TDS group (Continued)
Missing 1 (2.3%) 3 (5.5%)
Residual disease at SDS, mm
0 38 (88.4%) 44 (80.0%) 0.092
0–10 1 (2.3%) 8 (14.5%)
≧10 2 (4.7%) 1 (1.8%)
Missing 2 (4.7%) 2 (3.6%)
Recurrence at TDS
Age, median (range), years 61.5 (40–78) 58.6 (33–80)
<60 17 (39.5%) 28 (50.9%) 0.262
≧60 26 (60.5%) 27 (49.1%)
CA 125 (U/ml)
<100 31 (72.1%) 30 (54.5%) 0.040
≧100 7 (16.3%) 19 (34.5%)
Missing 5 (11.6%) 6 (10.9%)
Peritonitis carcinomatosa
No 40 (93.0%) 46 (83.6%) 0.042
Yes 0 (0%) 5 (9.1%)
Missing 3 (7.0%) 4 (7.3%)
Sites of recurrence
Peritoneal 28 (65.1%) 48 (87.3%) 0.009
Extra-peritoneal 15 (34.9%) 7 (12.7%)
Number of recurrence
Single 24 (55.8%) 17 (30.9%) 0.013
Multiple 19 (44.2%) 38 (69.1%)
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Fig. 2 Kaplan–Meier plot of survival rates after SDS. The survival rate was significantly better in the TDS group than in the non-TDS group (P <
0.001). The median OS after SDS was 123 months in the TDS group and 42 months in the non-TDS group. SDS secondary debulking surgery, TDS
tertiary debulking surgery, OS overall survival
Table 2 Patients characteristics at the time of quaternary debulking surgery (QDS)
Author Year Number FIGO stage (n) Agea Residual disease (n) Median CA125 (U/ml) Chemotherapy (n) Median OS (m)b
Shih et al. 2010 15 I (1) 54.1 0 mm (10) NA Yes (9) 34.8, 10.1 (from TDS)c
II (2) >0 mm (5) No (6)
III (9)
IV (1)
Fotopoulou et al. 2013 49 I (6) 57 0 mm (16) 736 Yes (18) 23.05 (from QDS)
II (6) >0 mm (33) No (31)
III (33)
IV (1)
Bacarubasa et al. 2015 20 I (4) 54.3 0 mm (7) NA NA 16 (from QDS)
II (5) >0 mm (13)
III (11)
IV (0)
Hirakawa et al. 2017 11 I (0) 57 0 mm (7) 11.2 (6 cases) Yes (4) 123 (from SDS)
II (1) >0 mm (2) No (7)
III (7) Missing (2)
IV (3)
QDS quaternary debulking surgery, NA data were not available
aThe values are the median age at QDS
bThe values are the median overall survival (OS)
cFor residual disease ≤10 mm, the median OS was 34.8 months; for residual disease >10 mm, the median OS was 10.1 months
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SDS at first recurrence). At the time of TDS (i.e., recur-
rence after SDS), more patients in the non-TDS group
had a recurrence in the peritoneal cavity, compared to the
TDS group (P = 0.009). Moreover, more patients showed
single-site recurrence in the TDS group than in the non-
TDS group (P = 0.013). Many cases of peritoneal cavity re-
currence involved wide peritoneal dissemination. These
patients may have selected chemotherapy instead of TDS.
In the TDS group, 11 patients underwent QDS and two
of these 11 patients underwent a fifth debulking surgery.
Ten (90.9%) of the 11 patients with FIGO stage III and IV
cancers were in the QDS group. This study included higher
ratio of advanced stage cancer patients, compared to other
reports on patients with QDS (Table 2). Based on these re-
sults, we believe that this is a valuable study to clarify the
current status of TDS or additional debulking surgeries.
There are several limitations of this study. One of two
main limitations is the retrospective nature of the study.
The second main limitation is the small sample size per
year and the small number of institutions. Among the 164
patients over 14 years, only approximately 12 patients
underwent SDS per year across 20 institutions. We as-
sumed that very few Japanese patients were treated with
SDS. Therefore, we collected data from many hospitals in
Japan. Despite the smaller sample size per institution, this
study provides valuable data concerning TDS and QDS.
A third limitation is the potential for selection bias, such
as similar tumor sizes and number of relapse sites. This bias
might influence the presence of residual tumor after
debulking surgery and/or the survival time. In future stud-
ies, selection bias in evaluating the efficacy of SDS and TDS
needs to be overcome. We could not rule out the possibility
that only highly selected patients were operated on in the
present study; nevertheless, this is a valuable study on the
current status of SDS and TDS. To the best of our know-
ledge, this is the first report on TDS and QDS in Japan.
Conclusions
In conclusion, several novel agents such as monoclonal
antibodies are being evaluated, although debulking sur-
gery remains an important treatment option for multiple
relapses. The present study demonstrated that, at second
recurrence, patients who were treated with TDS showed
a favorable OS, compared to patients treated with
chemotherapy or best supportive care. Further reports of
patients treated with SDS or additional debulking sur-
gery need to be accumulated to evaluate treatment re-
sults and confirm our findings.
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